GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » YoY EPS Growth

Solvonis Therapeutics (LSE:SVNS) YoY EPS Growth : 0.00% (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Solvonis Therapeutics's YoY EPS Growth for the quarter that ended in Sep. 2024 was 0.00%.

Solvonis Therapeutics's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was £0.00.

Solvonis Therapeutics YoY EPS Growth Historical Data

The historical data trend for Solvonis Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solvonis Therapeutics YoY EPS Growth Chart

Solvonis Therapeutics Annual Data
Trend May18 May19 May20 May21 Dec22 Dec23 Dec24
YoY EPS Growth
Get a 7-Day Free Trial 28.57 20.00 -550.00 -15.38 96.67

Solvonis Therapeutics Quarterly Data
May18 May19 May20 May21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 100.00

Solvonis Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Solvonis Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-0.03--0.026)/ | -0.026 |
=-15.38 %

Solvonis Therapeutics's YoY EPS Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EPS Growth (Q: Sep. 2024 )
=(Earnings per Share (Diluted) (Q: Sep. 2024 )-Earnings per Share (Diluted) (Q: Jun. 2023 )) / | Earnings per Share (Diluted) (Q: Jun. 2023 )) |
=(-0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solvonis Therapeutics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Solvonis Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » YoY EPS Growth
Comparable Companies
LSE:EQT LSE:SNT LSE:XSG XTER:SIE XPAR:SU ETN GEV PH OSTO:ATCO A ITW TSE:7011 XTER:ENR EMR CMI AME OTIS XSWX:SCHN IR OHEL:KNEBV XYL
Traded in Other Exchanges
N/A
Address
Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Website
https://www.solvonis.com
Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Solvonis Therapeutics Headlines

No Headlines